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Secretory leucoprotease inhibitor (SLPI) is a nonglycosylated protein produced by epithelial 
cells. In addition to its antiprotease activity, SLPI has been shown to exhibit antiinflammatory 
properties, including down-regulation of tumor necrosis factor 
 

 
 expression by 
lipopolysaccharide (LPS) in macrophages and inhibition of nuclear factor (NF)-
 

 
B 
activation in a rat model of acute lung injury. We have previously shown that SLPI can 
inhibit LPS-induced NF-
 

 
B activation in monocytic cells by inhibiting degradation of I
 

 
B
 

 
 
without affecting the LPS-induced phosphorylation and ubiquitination of I
 

 
B
 

 
. Here, we 
present evidence to show that upon incubation with peripheral blood monocytes (PBMs) 
and the U937 monocytic cell line, SLPI enters the cells, becoming rapidly localized to the 
cytoplasm and nucleus, and affects NF-
 

 
B activation by binding directly to NF-
 

 
B binding 
sites in a site-specific manner. SLPI can also prevent p65 interaction with the NF-
 

 
B 
consensus region at concentrations commensurate with the physiological nuclear levels of 
SLPI and p65. We also demonstrate the presence of SLPI in nuclear fractions of PBMs and 
alveolar macrophages from individuals with cystic fibrosis and community-acquired pneumonia. 
Therefore, SLPI inhibition of NF-
 

 
B activation is mediated, in part, by competitive binding 
to the NF-
 

 
B consensus-binding site.
 
Secretory leucoprotease inhibitor (SLPI) is an
11.7-kD nonglycosylated protein produced at
mucosal surfaces, primarily the upper respira-
tory tract (1). SLPI forms inhibitory complexes
with a variety of proteolytic enzymes, including
neutrophil elastase, and therefore appears to be
an important component of the antiprotease
defense of the lung (2). The amino acid sequence
of SLPI and the resulting nuclear magnetic
resonance solution structure has revealed a
protein composed of two highly homologous
domains of 53 and 54 amino acids, 8 disulfide
bridges in total, and a large number of positively
charged residues (3).
Recently, it has been demonstrated that
SLPI also possesses antiinflammatory, antiviral,
and antibacterial activity (4). LPS hyporesponsive
cells have been shown to transcribe SLPI and
transfection of macrophages, with SLPI suppress-
ing LPS-induced activation of NF-
 

 
B and
production of nitric oxide and TNF-
 

 
 by an
unknown mechanism (5). In addition, IFN-
 

 
can suppress expression of SLPI and restore LPS
responsiveness to SLPI-producing cells (5). SLPI
has also been shown to inhibit HIV infectivity
of monocytes by blocking viral DNA synthesis
by a mechanism that does not involve binding
to HIV directly but is most likely due to inter-
action with the host cell (6). In a model of
acute lung injury induced by intrapulmonary
deposition of IgG immune complexes in rats,
prior administration of SLPI attenuated pulmo-
nary recruitment of neutrophils and decreased
lung injury (7). In addition, prior administration
of SLPI to these animals resulted in greatly
reduced NF-
 

 
B activation in whole lung sam-
ples. Although, interestingly, down-regulation
of NF-
 

 
B activation was not observed in alveolar
macrophages (AMs) isolated by broncholaveolar
lavage from these animals (7). Further investi-
gation of the NF-
 

 
B regulatory proteins revealed
that I
 

 
B
 
 
 
degradation was prevented in animals
pretreated with SLPI. These data suggest that
the inhibitory effects of SLPI are selective for
the signal transduction pathway leading to
NF-
 

 
B activation. SLPI has been shown to in-
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hibit LPS and lipoteichoic acid (LTA)-induced NF-
 

 
B acti-
vation in monocytic cells by preventing degradation of key
regulatory proteins, such as I
 

 
B
 

 
 and I
 

 
B
 

 
 (8, 9). However,
SLPI does not prevent LPS-induced phosphorylation or poly-
ubiquitination of I
 

 
B
 

 
 and has no apparent inhibitory effect
on peptidase activities associated with the 20S proteasome,
which is responsible for degrading polyubiquitinated I
 

 
B
 

 
(8). An SLPI knockout mouse model has been demonstrated
to develop septic shock after peritoneal administration of LPS,
underlining the pivotal role played by SLPI in attenuating ex-
cessive inflammatory responses (10).
Our previous work showing inhibition of LPS-induced
NF-
 

 
B activation in monocytic cells without affecting other
features, such as I
 

 
B
 

 
 phosphorylation and polyubiquitina-
tion, would indicate that SLPI might be mediating its effects
internally after cell uptake (8). In this study, we show that
SLPI is taken up into monocytes and becomes distributed
within the cytoplasm and nucleus. We demonstrate that SLPI
can bind DNA, and using chromatin immunoprecipitation
(ChIP), we show that SLPI can bind to NF-
 

 
B regions
within the IL-8 and TNF-
 

 
 promoters but not the IL-10
promoter region, which contains no NF-
 

 
B binding site. We
also show by ChIP that p65 binding to the NF-
 

 
B regions
within the IL-8 and TNF-
 

 
 promoters is inhibited in the
presence of SLPI. In addition, we demonstrate that SLPI can
bind specifically to labeled NF-
 

 
B consensus oligonucleotide
sequence and diminish recombinant p65 binding. Finally, we
demonstrate that SLPI is present in the nucleus of peripheral
blood monocytes (PBMs) and AMs isolated from individuals
with sepsis. Our results indicate that SLPI may attenuate in-
flammation in monocytes, in part, by binding NF-
 

 
B sites of
proinflammatory immune response genes, thus preventing
p65 binding and subsequent transactivation of these genes.
 
RESULTS
SLPI uptake into monocytes
 
Cell binding and uptake studies.
 
U937 cells were incu-
bated with fluorescently labeled SLPI, and the level of cell
association was quantified using a spectrofluorimeter. A
highly significant level of SLPI cell association was seen after
just 1 h (Fig. 1). The level of cell association appeared to be
time-dependent with increasing levels of cell association seen
after longer incubations. A widely used tool for inhibiting
transport processes is to apply a temperature block to cells.
The results indicated that the binding and uptake of SLPI by
U937 cells are significantly inhibited (P 
 

 
 0.01) at a low
temperature (Fig. 1). The role of endocytosis was assessed
by pretreating cells with the endocytosis inhibitors (sodium
azide, sodium fluoride, and antimycin A) that inhibit glycol-
ysis and oxidative metabolism required for most endocytic
processes. These inhibitors had no significant effect on SLPI
cell association (not depicted).
 
Intracellular distribution.
 
The cell-association studies pro-
vide little information on the fate of SLPI within the cells
or on the degree of internalization versus binding. To this
end, confocal laser scanning microscopy of the fluorescein-
labeled protein was performed to determine the distribution
of SLPI within cells. The distribution of SLPI within U937
cells is shown in Fig. 2 A, and the intracellular distribution of
SLPI within PBMs is shown in Fig. 2 B. The uptake of SLPI
into cells was rapid and widespread (Fig. 2, A and B). The
protein is not simply bound to the cell membrane. It is inter-
nalized efficiently as evidenced by the high level of fluores-
cence within the cells. Fluorescein alone does not enter cells
to a significant extent, and therefore, the probe is being car-
ried into the cell by SLPI.
Figure 1. The level of cell association of SLPI-fluorescein with 
U937 cells. Cells were treated for 4 h with 10 g/ml SLPI-fluorescein at 
37 or 4C. n  3; mean 	 SD; **, P  0.01.
Figure 2. (A) Uptake of SLPI-fluorescein into U937 cells. 10 g/ml 
SLPI-fluorescein was incubated with U937 cells for 1 h. (i) Untreated U937 
cells. (ii) Treated U937 cells. (B) Uptake of SLPI-fluorescein into PBMs. 
10 g/ml SLPI-fluorescein was incubated with PBM for 1 h. (i) Untreated 
monocytes. (ii) Treated monocytes.
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Nuclear import studies.
 
To confirm and visualize the de-
gree of nuclear import of SLPI (Fig. 3, A and B, green), a
nuclear counterstain propidium iodide (red) was used. The
results are shown in Fig. 3 with colocalization represented by
yellow on the confocal image. The degree of colocalization
is also represented by a pixel intensity graph across one of the
PBMs (Fig. 3 C).
 
Western analysis.
 
SLPI distribution in the cytoplasmic
and nuclear compartments of U937 cells and PBMs was as-
sessed by Western analysis. As shown in Fig. 4, SLPI was de-
tected in the cytoplasmic and nuclear fractions of treated
U937 cells (A) and PBMs (B). Western analysis of untreated
U937 cells and PBMs revealed an absence of SLPI signal, in-
dicating that both cells do not make appreciable quantities of
SLPI that could be detected at this level. The purities of pre-
pared extracts were confirmed by probing for cytoplasmic-
and nuclear-specific proteins. As shown in Fig. 4 (A and B),
GAPDH was detectable only in the cytoplasmic extract (ii),
whereas Lamin B was only visible in the nuclear extract (iii).
Equivalent amounts of GAPDH and Lamin B indicated equal
loading for cytoplasmic and nuclear fractions, respectively.
 
SLPI interaction with DNA
 
Binding to genomic DNA.
 
Due to SLPI’s localization to
the nucleus and its cationic charge, we considered the likeli-
hood that SLPI could bind DNA directly. As shown in Fig. 5
A, SLPI was confirmed to bind to genomic DNA and, once
bound, required up to 500 mM NaCl to be eluted. SLPI did
not bind nonspecifically to the cellulose matrix (not depicted).
 
SLPI binding to NF-
 

 
B oligonucleotide.
 
Due to SLPI’s
ability to inhibit LPS- and LTA-induced NF-
 

 
B activation,
and with the new information presented above that SLPI can
localize to the nucleus and bind DNA, we considered the
possibility that SLPI might bind directly to NF-
 

 
B binding
sites. In Fig. 5 B, we demonstrate increased SLPI binding to
wild-type biotinylated NF-
 

 
B consensus oligonucleotide in a
dose-dependant manner. To test for the specificity of bind-
ing, a fixed amount of SLPI (100 ng) was incubated with
wild-type biotinylated NF-
 

 
B consensus oligonucleotide and
mutant NF-
 

 
B oligonucleotide, which contains a single base
change rendering it unable to bind NF-
 

 
B. We demonstrate
in Fig. 5 C (i and ii) that SLPI can bind with much greater af-
finity to wild-type NF-
 

 
B consensus oligonucleotide com-
Figure 3. Nuclear import of SLPI-fluorescein in PBMs. 10 g/ml 
SLPI-fluorescein (green) was incubated with monocytes for 1 h 
followed by counterstaining with propidium iodide. Red, nuclear stain. 
(A and B) Treated monocytes and (C) intensity profile. Red line, propidium 
iodide; green line, SLPI. (B) A magnification of the bottom left-hand 
quadrant of panel A.
Figure 4. SLPI cytoplasmic and nuclear distribution in (A) U937 cells 
and (B) PBMs. Cells were incubated with 10 g/ml SLPI for 1 h followed by 
isolation of cytoplasmic and nuclear fractions. Lane 1, untreated cytoplasmic 
fraction; lane 2, untreated nuclear fraction; lane 3, SLPI-treated cytoplasmic 
fraction; lane 4, SLPI-treated nuclear fraction subjected to Western blot and 
probed using antibodies to (i) SLPI, (ii) GAPDH, and (iii) Lamin B.
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pared with binding to the mutant oligonucleotide. This result
indicates SLPI’s preference for binding to NF-
 

 
B sites, corre-
sponding with its ability to inhibit NF-
 

 
B activation in acti-
vated U937 cells (8, 9). SLPI interaction with other con-
sensus transcription factor binding sites was also assessed.
Although there was no binding of SLPI to GATA-1, Sp-1, or
CREB consensus oligonucleotides, strong binding of SLPI to
AP-1 probe was observed (Fig. 5 D), indicating that SLPI
may also bind sites other than NF-
 

 
B.
 
Competition studies.
 
To assess the ability of SLPI to
compete for binding to NF-
 

 
B DNA sites compared with
p65, we incubated a fixed amount of recombinant p65 (100
ng) with various concentrations of SLPI (1–2,000 ng). p65–
DNA complexes were detected by electromobility shift assay
(EMSA). In the presence of increasing SLPI concentrations
(10–2,000 ng), the intensity of the p65–NF-
 

 
B DNA com-
plex signal decreased (Fig. 6 A). At concentrations of 1,000
and 2,000 ng, SLPI markedly suppressed the binding of 100
ng p65 to NF-
 

 
B consensus oligonucleotide (Fig. 6 A, lanes 5
and 6). In these lanes, increased SLPI–oligonucleotide com-
plexes could also be observed. A densitometry curve for SLPI
Figure 5. (A) SLPI binds to DNA. 2 g SLPI was incubated with DNA-
cellulose matrix, eluted in increasing amounts of NaCl, and subjected to 
Western blotting. Lane 1, flow through; lane 2, 150 mM NaCl elution; lane 
3, 300 mM NaCl elution; lane 4, 500 mM NaCl elution; lane 5, 750 mM 
NaCl elution. (B) SLPI binding to biotin-labeled NF-B consensus oligonu-
cleotide. Various amounts of SLPI (1–50 ng) were incubated with labeled 
NF-B oligonucleotide in the presence of poly(dI-dC·dI-dC): poly(dI-dC·dI-dC) 
and then electrophoresed on a 5% polyacrylamide gel. Lane 1, labeled 
oligonucleotide alone; lane 2, labeled oligonucleotide plus 1 ng SLPI; 
lane 3, labeled, oligonucleotide plus 2 ng SLPI; lane 4, labeled oligonucleotide 
plus 5 ng SLPI; lane 5, labeled oligonucleotide plus 10 ng SLPI; lane 6, 
labeled oligonucleotide plus 50 ng SLPI. (C, i) SLPI interaction with wild-
type (WT) and mutant (Mut) NF-B oligonucleotides. 100 ng SLPI was 
incubated with equal amounts of biotin-labeled wild-type NF-B con-
sensus oligonucleotide (lane 1) or mutant NF-B oligonucleotide (lane 2). 
(ii) Densitometry graph of SLPI binding to wild-type versus mutant NF-B 
oligonucleotide, representative of five experiments. (D) SLPI interaction 
with biotin-labeled GATA-1 (lane 1), Sp-1 (lane 2), CREB (lane 3), and AP-1 
(lane 4) consensus oligonucleotides.
Figure 6. (A) Increasing SLPI concentration prevents p65 binding 
to the NF-B site. EMSA: 10–2,000 ng SLPI was incubated with NF-B 
consensus binding site for 15 min followed by incubation with fixed 
amounts of p65 (100 ng) for an additional 20 min. Lane 1, p65 plus NF-B 
DNA; lane 2, 10 ng SLPI plus p65 plus NF-B DNA; lane 3: 100 ng SLPI plus 
p65 plus NF-B DNA; lane 4, 500 ng SLPI plus p65 plus NF-B DNA; lane 
5, 1,000 ng SLPI plus p65 plus NF-B DNA; lane 6, 2,000 ng SLPI plus p65 
plus NF-B DNA. P65–oligonucleotide and SLPI–oligonucleotide complexes 
are shown. (B) Densitometric evaluation of SLPI inhibition of p65 binding 
to NF-B consensus oligonucleotide. (C, i) Increasing SLPI concentration 
prevents p65 binding to NF-B site. p65 activity ELISA: 10–1,000 ng SLPI 
was incubated in wells containing the NF-B consensus oligonucleotide 
for 15 min followed by incubation with fixed amounts of p65 (10 ng). p65 
binding was detected by anti-p65 antibody/peroxidase-linked secondary 
antibody. (ii) SLPI displacement of p65 binding to NF-B oligonucleotide. 
(D) p65 nuclear localization in U937 cells treated with (i) LPS or (ii) SLPI/LPS. 
U937 cells were incubated with 1 g/ml LPS or 10 g/ml SLPI for 1 h 
followed by LPS. Nuclear fractions were prepared and probed for NF-B 
p65 over time. Lane 1, control; lane 2, 30 min; lane 3, 60 min; lane 4, 120 
min. (E) SLPI and p65 concentrations in 106 cells. Nuclear extracts from 
SLPI-incubated U937 cells were subjected to Western blot, and SLPI and 
p65 levels were estimated by densitometry using SLPI and p65 standards. 
p65  5.61 	 0.47 ng; SLPI  194 	 3.03 ng.
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inhibition of p65 binding to NF-B oligonucleotide is shown
in Fig. 6 B. In addition, we also demonstrated that SLPI could
prevent recombinant p65 binding to NF-B oligonucleotide
in a p65 activity ELISA (Fig. 6 C, i), with similar results to
those shown in panels A and B, as well as displace p65 from
binding to the NF-B oligonucleotide (Fig. 6 C, ii).
p65/SLPI nuclear localization and concentration in acti-
vated U937 cells. To determine the physiological rele-
vance of this effect, we performed two experiments to as-
certain: (a) whether p65 still localized to the nucleus after
activation with LPS in the presence of SLPI and (2) the
concentration of SLPI and p65 in the nuclear compartment
of U937 cells after incubation with SLPI and LPS. As shown
in Fig. 6 D, p65 localized to the nucleus of U937 cells
within 30 min after stimulation with LPS. Likewise, the ki-
netics of p65 localization to the nucleus was very similar in
the presence of SLPI/LPS, indicating that inhibition of NF-
B activation in these cells was not due to exclusion of p65
from the nucleus. p65 and SLPI levels in the nucleus of acti-
vated U937 cells were determined by densitometric analysis
of nuclear fractions separated by SDS-PAGE and blotted for
the respective protein. Fig. 6 E reveals that the amount of
p65 in the nucleus of activated U937 cells was 5.61 	 0.47
ng compared with the amount of SLPI in the same fraction,
which was 194 	 3.03 ng. This result revealed that SLPI
levels were 35-fold higher than p65, indicating that SLPI
could inhibit p65 binding to NF-B sites in the genome ac-
cording to the results obtained in Fig. 6 (A and B).
SLPI interaction with NF-B sites in the genome. Be-
cause SLPI is distributed in the nucleus of monocytic cells and
interacts with NF-B sites, we tested to see whether SLPI
could interact with an endogenous NF-B–rich promoter re-
gion. To this end, we investigated the binding of SLPI to the
IL-8 and TNF- promoters, which contain multiple NF-B
binding sites, and the IL-10 promoter, which contains no NF-
B sites, in U937 cells. U937 cells treated with or without
SLPI were fixed with formaldehyde and subjected to ChIP
analysis as outlined in Materials and methods. As shown in
Fig. 7, SLPI could bind to the IL-8 and TNF- promoters,
but did not interact with the IL-10 or GAPDH promoters. In
contrast, p65 binding to the TNF- and IL-8 promoters was
observed in cells treated with LPS alone (as expected), but not
in those cells preincubated with SLPI (Fig. 7).
Effect of SLPI on LPS-induced cytokine production. To
determine the effect of SLPI on LPS-induced cytokine pro-
duction, U937 cells were differentiated to a macrophage lin-
eage, and LPS-induced TNF-, IL-8, and IL-10 production
in the presence of SLPI was assessed. As can be seen in Fig.
8, SLPI decreased LPS-induced TNF- (LPS:1,420 	 26.8
pg/ml vs. SLPI/LPS: 914.3 	 47.1 pg/ml) and IL-8 produc-
tion (LPS: 599.2 	 15.4 pg/ml vs. SLPI/LPS: 340.2 	 4.0
pg/ml), but not IL-10 (LPS: 219.7 	 0.8 pg/ml vs. SLPI/
LPS: 223.2 	 4.3 pg/ml).
Presence of SLPI in PBM and AM nuclear fractions. AMs
and PBMs were isolated from six individuals with pulmonary
sepsis—three with cystic fibrosis (
F508 homozygous) and
three with community-acquired pneumonia—as well as from
three healthy controls (AMs and PBMs). Nuclear fractions
were prepared from both cell populations, and SLPI was mea-
sured by ELISA. SLPI was shown to be present in AM
(17,897 	 4,508 pg/106 cells) and PBM (133.9 	 34.4 pg/
106 cells) nuclear fractions from sepsis patients (Fig. 9). SLPI
was also present in control AMs (13,499 	 3,768 pg/106 cells)
but could not be detected in control PBMs (Fig. 9).
DISCUSSION
Previous studies have demonstrated SLPI’s ability to inhibit
LPS-induced NF-B activation in monocytes and macro-
Figure 7. Interaction of SLPI with NF-B sites in genomic DNA. 
U937 cells were incubated with or without 10 g/ml SLPI for 1 h and then 
1 g/ml LPS for 1 h, and DNA was isolated by ChIP. U937 cells were incu-
bated with anti-SLPI IgG, anti-p65 IgG, anti-acetyl histone H3 (positive 
control), or no antibody (negative control). DNA interacting with SLPI was 
isolated and subjected to PCR for detection of IL-8 promoter region (A), 
TNF- promoter region (B), IL-10 promoter region (C), and GAPDH promoter 
(D). Lanes 1, 3, 5, and 7, cells incubated minus SLPI; lanes 2, 4, 6, and 8, 
cells incubated with SLPI; lanes 1 and 2, no antibody immunoprecipitation; 
lanes 3 and 4, SLPI antibody immunoprecipitation; lanes 5 and 6, p65 anti-
body immunoprecipitation (A and B only); lanes 7 and 8, acetyl histone H3 
antibody immunoprecipitation.
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phages as well as prevent TNF-, nitric oxide, and matrix me-
talloprotease production (5, 11). In this study, we show that
SLPI can enter monocytes rapidly in a temperature-depen-
dent process, becoming localized to the cytoplasm and nu-
cleus. The ability of SLPI to enter the nucleus is particularly
interesting due to the cationic nature of this protein and its
potential to bind negatively charged regions of DNA. We
show that SLPI can bind DNA and NF-B sites in a specific
manner. In addition, we show that SLPI can compete with
NF-B (p65) for binding to the NF-B DNA site, thereby
providing a mechanism by which SLPI can prevent LPS-
and LTA-induced NF-B activation in monocytes. Using
ChIP technology, we also prove that SLPI binds the NF-
B–rich region of the IL-8 promoter, but not the IL-10 pro-
moter, which possesses no NF-B binding sites. We also
showed by ChIP that p65 binding was inhibited in the pres-
ence of SLPI. Finally, we demonstrate that SLPI is present in
in vivo PBM and AM nuclear fractions.
Other proteins have been identified that are rapidly and
efficiently internalized by cells, e.g., Drosophilia homeotic
transcription protein antennapedia (Antp) and the human
immunodeficiency virus I transcriptional activator (HIV-
TAT), due to the presence of small regions called protein
transduction domains in their structure (12). The common
feature of these protein transduction domains is the high
content of lysine and arginine amino acids (13). A great deal
of debate still continues about the exact mechanism of pro-
tein transduction into cells. Initial studies conducted on Antp
and HIV-TAT indicated a nonendocytic uptake process for
these arginine-rich peptides, but it has recently been sug-
gested that the mechanism of uptake is very much protein-
dependent. A number of models have been devised to ex-
plain the ability of basic, hydrophilic peptides to translocate
across cell membranes, including the involvement of hydro-
gen bonding and membrane potential in the translocation
process (14). Therefore, it might be the arginine-rich nature
of SLPI that enables it to interact with the predominantly
negatively charged cell membrane and be internalized. In-
deed, it could be hypothesized that SLPI contains its own
unique protein transduction domain. There is recent evi-
dence to show that SLPI can bind to the cell surface protein
annexin II, which is present on the cell surface of macro-
phages, U937 cells, and PBMs (15, 16, 17).
Like most of the cationic proteins of the respiratory tract,
SLPI possesses antibacterial activity. However, it is clear that
many of these proteins can also exert proinflammatory or an-
tiinflammatory effects. The neutrophil-derived peptide LL-
37 can induce IL-8 expression in monocytes via ERK and
p38-dependent pathways (18) similar to  defensins, which
can also induce IL-8 expression by epithelial cells (19). In
contrast, lactoferrin, which is one of the most abundant cat-
ionic proteins of the airways, can inhibit LPS-induced IL-8
expression by epithelial cells. Similar to the data presented in
this study, lactoferrin has also been shown to enter cells be-
coming localized to the nucleus (20). Lactoferrin’s interac-
tion with DNA has also been verified, although its ability to
up-regulate AP-1 activity in fibroblasts is not due to direct
binding and transactivation of the AP-1 promoter site (21).
Another peptide, PR-39, has also been shown to enter cells
and inhibit TNF-–induced effects by binding directly to
subunits of the proteasome, thus affecting degradation of
Figure 8. Effect of SLPI on LPS-induced TNF- (A), IL-8 (B), and 
IL-10 (C) protein production by U937 macrophages.
Figure 9. Measurement of SLPI in the nucleus of AMs and PBMs. 
Nuclear fractions were prepared from 106 AMs or PBMs from individuals with 
sepsis (cystic fibrosis and community-acquired pneumonia) and healthy 
controls. SLPI levels were determined by ELISA. Con, control; Sep, sepsis.
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polyubiquitinated, phosphorylated IB (22). We have pre-
viously shown that SLPI can prevent degradation of IB
and  and subsequently inhibit NF-B activity without af-
fecting IB phosphorylation and ubiquitination (8). But in
this study, we have demonstrated that p65 can still translo-
cate to the nucleus in SLPI-treated cells. Therefore, how
does SLPI prevent IB degradation and at the same time
allow p65 entry to the nucleus? These diverging effects may
occur as a result of SLPI’s multifunctional characteristics of
size, charge, and protease inhibition activity as we will now
explain. Due to SLPI’s inhibition of p65, it might be ex-
pected that SLPI would be proapoptotic. However, we have
generated some data to show that instead of increasing TNF-
–induced caspase-3 activation in U937 cells, SLPI in fact
decreases TNF-–induced caspase-3 activity (not depicted).
It is possible that SLPI is interfering with apoptotic pathways
in the cell, most of which are controlled by proteases, partic-
ularly caspases, and that SLPI might be inhibiting one of
these proteases directly. Interestingly, caspase-3 has been
shown previously to cleave IB (23). This raises the possi-
bility that SLPI may inhibit caspase-3–mediated IB cleav-
age and that our previous finding, demonstrating SLPI inhi-
bition of LPS-induced IB degradation (8), might be due
in part to SLPI’s antiapoptotic effect as opposed to any direct
effect on the ubiquitin–proteasome pathway. Therefore,
SLPI inhibition of caspase activity may lead to accumulation
of a certain amount of phosphorylated, polyubiquitinated
IB, whereas a certain amount of IB may still be de-
graded by the proteasome, allowing release of p65 from the
NFB–IB complex. Our current findings, demonstrating
SLPI binding to NF-B DNA sites, might be antiprotease-
independent and occur as a result of SLPI’s relatively small
size (allowing it to passively diffuse into the nucleus) and its
positive charge (allowing it to bind to negatively charged
DNA, albeit in a specific manner).
Studies in SLPI knockout mice have demonstrated that
these develop septic shock when challenged peritoneally
with LPS (10). This was explained in part by increased activ-
ity of the transcription factors NF-B and C/EBP- in mac-
rophages from SLPI/ mice compared with SLPI/ mice.
These findings lend support to our own observations that
SLPI can inhibit NF-B activity by interacting directly with
NF-B binding sites and subsequently inhibiting p65 bind-
ing. We have also evaluated SLPI binding to other transcrip-
tion factor binding sites, including GATA-1, Sp-1, CREB,
and AP-1. Although we did not observe binding of SLPI to
GATA-1, Sp-1, and CREB, we did observe SLPI binding to
the AP-1 transcription factor binding site. AP-1 is involved
in a number of processes, including inflammation and cell
proliferation, and future studies will be aimed at elucidating
the AP-1–dependent effects of SLPI. It is possible that some
of the effects that we have seen on TNF- and IL-8 produc-
tion in this study (Fig. 8) are due in part to an effect of SLPI
on AP-1 activity. However, it has been shown previously
that LPS-induced IL-8 production from macrophages is de-
pendent on NF-B activity (24). To determine further the
specific effects of SLPI on AP-1 activity as compared with
NF-B, an approach using siRNA to p65 or ATF-2/c-jun
(subunits of AP-1) and the subsequent effect of SLPI on
LPS-stimulated cytokine production in siRNA-transfected
U937 cells will provide more definitive data.
Other studies in support of our findings in this study
have demonstrated that cyclin D1 gene expression is in-
creased in an SLPI knockout cell line compared with the pa-
rental cell line and that this activity is due in part to SLPI
regulation of the cyclin D1 promoter (25). Interestingly,
NF-B is a transactivator of cyclin D1 gene expression, sug-
gesting that SLPI may also influence the regulation of this
gene by inhibiting NF-B binding. In addition, one of the
few augmentation trials involving the administration of SLPI
to the airways of individuals with cystic fibrosis resulted in
decreased IL-8 levels in the lungs of treated individuals (26).
This correlates well with our findings in this study in which
we have shown that SLPI can bind to the NF-B–rich pro-
moter region of the IL-8 gene in monocytes and, in so do-
ing, may inhibit NF-B activation of the IL-8 gene and sub-
sequent IL-8 protein production. Another previous study
has shown that SLPI can prevent LPS-induced TNF- pro-
duction in macrophages, and we have demonstrated here
that SLPI can bind to the NF-B–rich TNF- promoter (5).
We also investigated SLPI binding to the IL-10 promoter
and demonstrated an absence of SLPI binding to the pro-
moter region of this gene. However, it has been shown pre-
viously that IL-10 expression is regulated by MAP kinases
and Sp-1 (27, 28), but not NF-B (29).
Our finding that SLPI is present in the nucleus of human
PBMs and AMs also lends support to our observation that
SLPI can enter the nucleus of monocytes and macrophages.
We have demonstrated differences in SLPI concentrations in
the nucleus of both cell populations, which probably reflect
the SLPI concentration in the surrounding environment of
these cell types. Although SLPI levels can exceed 100 ng/ml
in serum, saliva levels of SLPI are in the range of 4–24 g/
ml and lung epithelial lining fluid levels of SLPI are as high
as 10 g/ml (30–32). This information and our findings in
this study would suggest that SLPI may exert its greatest
anti–NF-B effects in the respiratory/upper respiratory tract
in vivo. Therefore, the use of SLPI as an augmentation ther-
apy directed toward inhibiting NF-B would necessitate
augmentation levels that would reach 10 g/ml and higher
to have an effect.
In conclusion, we have demonstrated that SLPI can enter
monocytic cells and become localized to the nucleus. We
have also shown that SLPI can bind an NF-B consensus se-
quence as well as the promoter region of the IL-8 gene in
monocytes and is capable of inhibiting p65 binding to the
NF-B DNA binding site. Therefore, our results may go
some way toward explaining SLPI’s immunomodulatory/
antiinflammatory role in suppressing NF-B–induced re-
sponses in monocytes.
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MATERIALS AND METHODS
All experiments were repeated at least three times.
SLPI intracellular localization
SLPI labeling. SLPI (R&D Systems) was fluorescently labeled using a dye
reagent (Fluorescein-EX; Invitrogen) that has a reactive succinimidyl ester
moiety, which reacts with the primary amines of the protein to form a sta-
ble SLPI-fluorescein conjugate. Free dye was removed using a Spin-OUT
column (Geno Technology) with a molecular weight cut-off of 6,000. The
yield after purification was quantified using a Bio-Rad Laboratories protein
assay, and the degree of labeling was determined by UV absorbance.
Cell culture. U937 cells were cultured routinely in RPMI containing
10% fetal calf serum. PBMs were isolated from the blood of healthy volun-
teers using Ficoll-Paque separation from which the mononuclear cell layer
was removed and washed twice in RPMI. Monocytes were positively se-
lected using anti-CD14–coated magnetic beads (Miltenyi Biotec) and resus-
pended in RPMI/10% fetal calf serum.
Cellular binding and uptake assays. Before treatment, the medium was
removed from U937 cells and replaced with fresh medium. The cells were
seeded onto 24-well plates (Nunc), and SLPI-fluorescein was added to each
well and incubated at 37C under 5% CO2. After incubation, the cells were
washed three times with PBS and incubated with 1 ml Triton X-100 (1%
wt/vol) for 30 min at 37C. Cell-associated fluorescence was determined at
excitation and emission wavelengths of 494 and 518 nm, respectively, on a
spectrofluorimeter (PerkinElmer) and expressed as fluorescence/mg protein
(Bio-Rad Laboratories protein assay kit).
To determine the mechanism of SLPI–cell interaction, incubations
were performed at 4C and in the presence of endocytosis inhibitors (0.1%
wt/vol sodium azide, 10 mM sodium fluoride, and 1 g/ml antimycin A).
Confocal laser scanning microscopy. 106/ml U937 cells or PBMs were
incubated with 10 g/ml SLPI-fluorescein for various time periods (10 min
to 4 h) followed by washing three times in PBS. 10,000 cells were then
cytospun onto glass microscope slides and air-dried. The cytospins were incu-
bated for 5 min in 1% wt/vol paraformaldehyde followed by washing three
times in PBS. Finally, some cytospins were incubated with 0.5 M propid-
ium iodide for 30 min in the dark and washed three times in PBS. Fluores-
cence-free glycerol-based mounting medium was added before covering the
slide with a coverslip for visualization. The cells were viewed using an upright
confocal microscope (LSM510 Axioplan 2; Carl Zeiss MicroImaging, Inc.).
Western blotting
Cytoplasmic and nuclear fractions from 10 g/ml of untreated and SLPI-
treated monocytes were prepared as described previously (8). The purity
of the fractions were tested by separating equal amounts of protein (10
g) on 10% SDS-PAGE and followed by transfer to nitrocellulose. West-
ern analysis was performed using antibodies to GAPDH (1:500 for cyto-
plasmic detection) and Lamin B (1:100 for nuclear detection) in 5% non-
fat skimmed milk and 1% BSA in PBST overnight at 4C. All antibodies
were from Santa Cruz Biotechnology, Inc. Antibody–antigen complexes
were detected using appropriate horseradish peroxidase–labeled second-
ary antibodies, and blots were developed using supersignal chemilumi-
nescent reagent (Pierce Chemical Co.). For detection of SLPI, 10 g of
cytoplasmic and nuclear fractions were separated on 15% SDS-PAGE,
transferred to nitrocellulose, and detected using a rabbit anti–SLPI IgG
(1:1,000) incubated overnight in 0.2% I-block (Tropix) in PBST. Anti-
body–antigen complex was detected using anti–rabbit horseradish perox-
idase for 1 h in 0.2% I-block (Tropix) in PBST, and the blot was devel-
oped as described above.
Activation of U937 cells by LPS. 106/ml U937 cells were incubated
alone, in the presence of 1 g/ml LPS (Escherichia coli B111:B4; Sigma-
Aldrich), or preincubated with 10 g/ml SLPI followed by 1 g/ml LPS
for 120 min as described previously (8, 9). Nuclear fractions were prepared
and equal amounts of protein (20 g) were separated by 15% SDS-PAGE. After
transfer to nitrocellulose, the blot was blocked in 5% nonfat skimmed milk
and 1% BSA and then incubated with mouse anti–p65 IgG overnight at
4C. The rest of the blotting procedure was performed as described above.
SLPI was also detected in the same samples (as described above), and levels
of SLPI and p65 were determined by densitometry using the GeneGenius
Gel Documentation and Analysis System (Syngene) as well as Syngene Gene-
Snap and GeneTools software. Comparison of p65 and SLPI in U937 nu-
clear fractions was made to fixed standards of recombinant SLPI and p65
separated on the same gels as the nuclear fractions.
DNA binding studies
Genomic DNA binding. To test SLPI binding to DNA, SLPI was incu-
bated with 4 mg of the bovine thymus genomic DNA–cellulose conjugate
(Sigma-Aldrich), or cellulose-type 50 (Sigma-Aldrich) was incubated with 2
g SLPI at 4C for 1 h in 20 mM Tris, pH 7.5, 100 mM KCl, 10% glyc-
erol, 1 mM EDTA, 1 mM DTT, 1 mg/ml BSA, 0.2% Triton X-100, and
protease inhibitor cocktail. The beads were thoroughly washed with 20
mM Tris, pH 7.5, 110 mM potassium acetate, 10% glycerol, 1 mM EDTA,
1 mg/ml BSA, and 0.2% Triton X-100. The beads were then equilibrated
in 20 mM Tris, pH 7.5, and elution was performed sequentially in PBS
with increasing concentrations of NaCl (from 150 to 750 mM). The eluate
was centrifuged at 960 g for 1 min, and the supernatant was used for analy-
sis. For Western blot analysis, proteins were resolved on a 15% SDS-PAGE
and transferred to a nitrocellulose membrane. SLPI was detected by West-
ern blot as indicated above.
EMSA. EMSA was performed as described previously with some modifi-
cations. Various concentrations of SLPI (1–2,000 ng) were incubated with
double-stranded wild-type biotinylated NF-B consensus oligonucleotide
(5-AGTTGAGGGGACTTTCCCAGGC-3; MWG Biotech) alone or in
the presence of 100 ng of recombinant p65 (Active Motif) for 30 min at
room temperature in binding buffer (4% [vol/vol] glycerol, 1 mM EDTA,
10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM DTT, and 0.1 mg/ml
nuclease-free BSA) and 2 g poly (dI-dC·dI-dC):poly(dI-dC·dI-dC):
(Sigma-Aldrich). In some experiments, double-stranded mutant biotin-
ylated NF-B oligonucleotide (5-AGTTGAGGCGACTTTCCCAGGC-
3; MWG Biotech) was added to test the specificity of SLPI binding. Reac-
tion mixtures were electrophoresed on native 5% (for detection of NF-B–
DNA complexes) or 15% (for detection of SLPI–DNA complexes) poly-
acrylamide gels. The gels were then transferred to nitrocellulose in 1X TBE
for 30 min at 380 mA, 100 V, and then cross-linked on a UV transillumina-
tor for 10 min. Nitrocellulose membrane was used in preference to nylon as
SLPI–NF-B probe complexes could not be detected on nylon membrane,
most likely due to the inability of the positively charged SLPI molecule to
bind to the positively charged nylon membrane. Detection of SLPI–DNA
or p65–DNA complexes was performed using the Chemiluminescent
Nucleic Acid Detection Module (Pierce Chemical Co.). In brief, after cross-
linking, the blot was incubated in blocking buffer for 1 h at 37C. Streptavi-
din-peroxidase was added for 15 min in blocking buffer at room tempera-
ture, and the blot was then washed six times in wash buffer. The blot was
incubated for 5 min in equilibration buffer and developed with the chemi-
luminescent reagents provided with the kit. SLPI inhibition of p65 binding
was determined by densitometry using the GeneGenius Gel Documenta-
tion and Analysis System (Syngene) as well as Syngene GeneSnap and
GeneTools software.
SLPI binding to other consensus oligonucleotide sequences. SLPI
binding to other transcription factor consensus oligonucleotide binding sites
was also tested as described above using 100 ng SLPI and the following bi-
otin-labeled double-stranded oligonucleotides: CGCTTGATGAGTCA-
GCCGGAA (AP-1), AATTGGACCGTATCTCCC (GATA), ATTC-
GATCGGGCGGGGCGAG (Sp-1), and AGAGATTGCCTGACGTCA-
GACAGCTAG (CREB).
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NF-B activity ELISA. The effect of SLPI on p65 binding activity was
determined using the TransAM NF-B ELISA (Active Motif). Initially, 10–
1,000 ng SLPI was incubated in 30 l binding buffer (DTT) and added to
wells containing the NF-B consensus oligonucleotide for 15 min at room
temperature with rotation. 10 ng of recombinant p65 (Active Motif) was
added to each well in 10 l of complete lysis buffer, and incubation was con-
tinued for an additional hour. After washing, 100 l anti-p65 antibody was
added to each well for 1 h without agitation followed by additional washing
and incubation with peroxidase-labeled secondary antibody without agitation.
After the final wash, 100 l developer solution was added to each well for 5
min followed by 100 l stop solution and then read at 450/650 nm on a plate
reader. In separate experiments to examine SLPI’s ability to displace p65 from
the NF-B oligonucleotide, 10 ng p65 was incubated in 30 l binding buffer
(DTT) and added to wells containing the NF-B consensus oligonucleotide
for 15 min at room temperature with rotation. 100 or 1,000 ng SLPI was
added to each well in 10 l of complete lysis buffer, and incubation was con-
tinued for an additional hour. Incubation with anti-p65 antibody/secondary
antibody and development were performed as described above.
ChIP
ChIP was performed using an EZ ChIP kit (Upstate Biotechnology). U937
monocytes were pretreated with or without 10 g/ml SLPI for 1 h and incu-
bated for an additional hour with 1 g/ml LPS. After culture, cells were cross-
linked in the cell culture plates by adding 37% formaldehyde to the culture me-
dium to a final concentration of 1% and incubating at room temperature for 10
min. The cross-linking reaction was stopped by the addition of 0.125 M glycine
for 5 min. Cells were washed with ice-cold PBS containing protease inhibitors
and lysed in SDS lysis buffer containing protease inhibitors. Samples were soni-
cated on ice to an average size of 200–1,000 bp and centrifuged for 10 min at
14,000 rpm at 4C to remove insoluble material. The supernatant was diluted
10-fold in ChIP dilution buffer containing protease inhibitors. Chromatin was
precleared with salmon sperm DNA/protein G agarose for 1 h at 4C, and 1%
of this solution was saved (input chromatin) and processed with the eluted im-
munoprecipitates beginning with the cross-link reversal step. Samples were in-
cubated overnight at 4C with 5 g goat anti–SLPI antibody, 5 g anti-p65 an-
tibody (sc-109x; Santa Cruz Biotechnology, Inc.), 10 g anti-acetyl histone H3
(positive control; Upstate Biotechnology), or no antibody (negative control)
with rotation. Immune complexes were collected by incubating samples with
salmon sperm DNA/protein G agarose for 1 h at 4C with rotation. The beads
were pelleted by brief centrifugation and washed as per the manufacturer’s in-
structions with low salt complex wash buffer, high salt complex wash buffer,
LiCl immune complex wash buffer, and TE buffer, pH 8.0. The immunocom-
plexes were eluted from the agarose beads by adding 200 l elution buffer (1%
SDS and 0.1 M NaHCO3), vortexing, and rotating at room temperature for 30
min. Input and immunoprecipitated chromatin were incubated with 200 mM
NaCl at 65C for 4 h to reverse DNA–protein cross-links. Samples were
RNase-treated for 30 min at 37C. 10 mM EDTA, 40 mM Tris-HCL, pH 6.5,
and 20 g proteinase K (Sigma-Aldrich) were then added to chromatin and in-
cubated at 45C for 1 h. Input DNA was recovered by phenol/chloroform ex-
traction and ethanol precipitation. Immunoprecipitated DNA was purified as
per the manufacturer’s instructions (Upstate Biotechnology). Promoter se-
quences were detected in input and immunoprecipitated DNA by PCR using
specific primers: IL-8 (forward: GGGCCATCAGTTGCAAATC; reverse:
TTCCTTCCGGTGGTTTCTTC); IL-10 (forward: AGAGGAAAG-
TAAGGGACCTCC; reverse: AGACTGGCTTCCTACAGGACA); TNF-
(forward: CCCTCCAGTTCTAGTTCTATC; reverse: GGGGAAAGAAT-
CATTCAACCA), and GAPDH (forward: TACTAGCGGTTTTACGG-
GCG; reverse: TCGAACAGGAGGAGCAGAGAGCGA).
Effect of SLPI on LPS-induced cytokine production
To assess the effect of SLPI on LPS-induced TNF-, IL-8, and IL-10 pro-
tein production, U937 cells were differentiated to a macrophage phenotype
by incubating with 100 ng/ml PMA for 48 h. The adhered cells were then
washed and incubated for an additional 3 d in fresh medium, washed again,
and resuspended in fresh medium. The cells were then incubated for an ad-
ditional 24 h in medium alone or with 100 ng/ml LPS, or they were prein-
cubated with 10 g/ml SLPI for 1 h followed by LPS for 24 h. TNF-, IL-8,
and IL-10 levels were measured in the cell supernatant using commercially
available ELISA kits (R&D Systems).
SLPI nuclear localization in vivo
To determine whether SLPI could be detected in the nucleus of in vivo
samples, PBMs were isolated from six individuals with pulmonary sepsis—
three with cystic fibrosis and three with community-acquired pneumonia.
PBMs were also isolated from three healthy controls. The cystic fibrosis pa-
tients were homozygous for the 
F508 CFTR mutation. In addition, AMs
were isolated from the same individuals. In brief, bronchoalveolar lavage
fluid was collected from each individual and centrifuged at 3,000 rpm for 10
min and washed twice in RPMI medium containing 10% fetal calf serum.
Macrophages were adhered to six-well tissue culture plates and cultured for
1 h followed by washing in medium. Adhered macrophages were scraped
from the wells in PBS and counted using trypan blue.
Cytoplasmic and nuclear extracts were prepared from the isolated PBM
and AM samples as described above in preparation for SLPI analysis by ELISA.
SLPI ELISA. Immunlon-2 96-well plates were coated with rabbit anti–
human SLPI antibody overnight at 4C in Voller’s buffer (1:1,000). The
plates were washed with PBST, and SLPI standards (2,000–31.25 pg/ml)
were applied to the plate in 100-l aliquots. The monocyte and AM nu-
clear samples were made up to 200 l in PBST, diluted 1:2 across the plate,
and left at room temperature for 2 h. The plates were then washed as be-
fore, and biotinylated anti–human SLPI antibody (R&D Systems) diluted
1:100 in PBST was loaded onto the plate in 100-l aliquots and left at room
temperature for 2 h. Finally, streptavidin-peroxidase (Zymed Laboratories)
diluted 1:2,500 in PBST was pipetted onto the plates in 100-l aliquots and
left at room temperature for 30 min. After a final wash, 100 l ABTS
(Zymed Laboratories) was added to each well, and the color was left to de-
velop. Absorbance values at 405 nm were converted to actual SLPI concen-
trations using GraphPad Prism software (GraphPad Software).
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